2020

HSCI scientist awarded grant to develop gene therapy for HIV

September 7, 2020

HSCI co-director David Scadden is part of a multi-institutional, cross-disciplinary team that has been awarded a $14.6 million grant from the National Institutes of Health. The team is using gene and cell therapy approaches to develop a potential cure for HIV.

The researchers will combine gene editing against HIV with technologies for safer and more effective blood stem cell transplants. Such transplants, also known as bone marrow transplants, are currently used for severe blood cancers. They renew a patient’s immune system, which can be damaged by cancer therapies, by...

Read more about HSCI scientist awarded grant to develop gene therapy for HIV

Lab1636 and Harvard University RFA on Rare Genetic Diseases

October 27, 2020

Harvard’s Office of Technology Development (https://otd.harvard.edu) is pleased to announce a Request for Applications (RFA) under the strategic research alliance between Harvard University and Lab1636. This 2020 RFA with Lab1636 and Harvard University is seeking proposals to develop innovative therapeutic strategies for Rare Genetic Diseases. Letter of Intents (LOIs) are due December 4, 2020 at 5:00 pm...

Read more about Lab1636 and Harvard University RFA on Rare Genetic Diseases

A global conference on the latest stem cell research

July 29, 2020

In June, the Harvard Stem Cell Institute (HSCI) co-sponsored the annual meeting of the International Society for Stem Cell Research. Held virtually for the first time, the conference brought together close to 4,000 scientists from 59 countries to discuss the latest in stem cell research.

David Scadden, co-director of HSCI, opened the conference by welcoming attendees and encouraging researchers to apply their expertise in stem cell science to the ongoing COVID-19 pandemic: “This has been a time of great crisis and upheaval that has really reminded us of the extraordinary power...

Read more about A global conference on the latest stem cell research

Pages